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Abstract
Background: Mutations in the genes PRKN and LRRK2 are the most frequent known genetic
lesions among Parkinson's disease patients. We have previously reported that in the Portuguese
population the LRRK2 c.6055G > A; p.G2019S mutation has one of the highest frequencies in
Europe.
Methods: Here, we follow up on those results, screening not only LRRK2, but also PRKN, SNCA
and PINK1 in a cohort of early-onset and late-onset familial Portuguese Parkinson disease patients.
This series comprises 66 patients selected from a consecutive series of 132 patients. This selection
was made in order to include only early onset patients (age at onset below 50 years) or late-onset
patients with a positive family history (at least one affected relative). All genes were sequenced bi-
directionally, and, additionally, SNCA, PRKN and PINK1 were subjected to gene dosage analysis.
Results: We found mutations both in LRRK2 and PRKN, while the remaining genes yielded no
mutations. Seven of the studied patients showed pathogenic mutations, in homozygosity or
compound heterozygosity for PRKN, and heterozygosity for LRRK2.
Conclusion: Mutations are common in Portuguese patients with Parkinson's disease, and these
results clearly have implications not only for the genetic diagnosis, but also for the genetic
counseling of these patients.
Background
Parkinson's disease (PD) is clinically characterized by rest-
ing tremor, rigidity, bradykinesia, and postural instability
[1]. The gold standard of PD diagnosis remains a patho-
logical one. Pathological hallmarks include cell loss in
pigmented nuclei and the formation of eosinophilic intra-
cytoplasmic inclusions, termed Lewy bodies, particularly
in the dopaminergic neurons of the substantia nigra pars
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clein; OMIM#163890), PRKN (Parkin OMIM#602544),
DJ1 (Oncogene DJ1 OMIM#602533), PINK1 (PTEN-
Induced Putative Kinase 1 OMIM#608309) and LRRK2
(Leucine-Rich Repeat Kinase 2 OMIM#609007) have
been implicated as causes of monogenic PD [4-9].
A missense mutation within SNCA encoding the protein
alpha-synuclein was the first identified genetic cause of
PD [6] and copy number mutations at this locus have also
been shown to cause familial PD [10]. Mutations in PRKN
are a common cause of autosomal recessive early-onset
parkinsonism [11,7], however mutations in PINK1 and
DJ-1 have also been reported as associated with this type
of parkinsonism, although only five causative mutations
have been described in the latter [12-14]. Mutations in the
gene LRRK2 are a common cause of autosomal dominant
and apparently sporadic PD. The LRRK2 mutation
c.6055G > A; p.G2019S, accounts for 1–2% of typical spo-
radic PD in the North American and Northern European
white population, with higher prevalence in Portuguese
(6%), Ashkenazi Jewish (18.3%) and North African Arab
populations (39%) [15-18].
We had previously shown that the c.6055G > A; p.G2019S
mutation in LRRK2 is common in Portuguese PD patients
[15]. Here we extend upon this study to search for addi-
tional LRRK2, SNCA, PRKN and PINK1 mutations in a
clinic-based cohort of patients, mainly from the central
region of Portugal.
Methods
After obtaining informed consent, 132 PD patients under-
went a standardized neurological examination by a move-
ment disorder specialist. The diagnosis of PD was based
on the UK Brain Bank diagnostic criteria (family history
was not used as an exclusion criterion) and those pub-
lished by Gelb et. al. [2,19]. Family history was considered
positive if parkinsonism was reported in at least a first- or
second-degree relative. Collection of these 132 patients
was performed at the Movement Disorder Clinics of both
the University of Coimbra Hospital and the Lisbon Hos-
pital Center – Center Region EPE in Lisbon, in a consecu-
tive manner, all patients consent to participate. This
cohort is identical to that previously described by us
except for the inclusion of 4 additional PD patients [15].
From this series of 132 subjects we have selected 66 unre-
lated patients to include only those with a positive family
history for parkinsonism, or early-onset disease (age at
onset <50 years of age). The remaining 66 patients failed
to meet either of these criteria, were related to a proband
already included or had previously been found to carry
the LRRK2 c.6055G > A; p.G2019S mutation (n = 11).
This selection led to the inclusion of 39 patients with pos-
itive family history and 46 patients with early-onset PD;
19 patients presented with both an early-onset phenotype
and a positive family history, thus the net number of
patients from both inclusion groups is 66 (Table 1).
Additionally we have included a control group comprised
of 126 healthy subjects as previously described [15].
Briefly, this control group consisted primarily of spouses
accompanying patients to the clinic (~80%); the remain-
ing controls were recruited from non-neurology outpa-
tient clinics, after observation by the movement disorders
specialist. This series presented a mean age of 60.5 ± 23.1
years. Apart from the spouses of the patients, no other
familiarity with movement disorders patients was found.
All individuals are Caucasian and of apparent Portuguese
ancestry.
Genomic DNA was extracted from peripheral blood using
standard methods. We screened the genes SNCA, PRKN,
PINK1 and LRRK2 for sequence variants and, with the
exception of LRRK2, for genomic copy number variants.
The reference sequence used for the PRKN gene through-
out this paper is based on the accession number
NM_004562 and codon counting starts from the first
ATG.
For SNCA, PRKN and PINK1, all exons were polymerase
chain reaction-amplified and sequenced in both direc-
tions using BigDye chemistry (Applied Biosystems, Foster
City, CA) on an ABI 3100 Genetic Analyzer as previously
described [7,20,21]. While for the LRRK2 gene, only exon
41 was screened for mutations, using conditions previ-
ously described [15].
Gene dosage analysis was performed using the ABI 7900
Sequence Detection System. Exons 1,2, 4–9 and 11–12 of
PRKN and exons 1 and 2 of SNCA, as well as the complete
coding region of PINK1 were individually co-amplified
with β-globin, which served as an endogenous reference
gene. Each plate contained six replicates of every genomic
DNA sample, control DNA, and a no-template water con-
trol. The cycle in the log phase of PCR amplification at
which a significant fluorescence threshold was reached
(Ct) was used to quantify each exon relative to β-globin.
Table 1: Features of patients studied, where more than one 
affected member was identified in a family only the presenting 
affected member (proband) is included.
Characteristic Subjects (n = 66)
Age at collection (mean ± SD) 60.1 ± 11.1
Age at onset (mean ± SD) 44.5 ± 9.3
Range of age at onset 20 – 60
Family history
Positive 39 (59.1)
Negative 27 (40.9)Page 2 of 6
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ized to control DNA was determined using the 2-ΔΔCt
method (Applied Biosystems, Foster City, CA).
Results
Analysis of both sequence and copy number yielded sev-
eral parkin mutations in our subset of patients. The posi-
tive results found are represented in Table 2, and the
electropherograms corresponding to point mutations are
shown in Figure 1. We found four patients in whom both
alleles were mutated; three of these patients had the same
homozygous mutation (c.154delA; p.N52fsX80), a single
base pair deletion that inserts a premature stop codon
downstream; one patient showed deletion of exon 2 and
duplication of exon 5; analysis of a sixth sample (S4)
showed data consistent with a homozygous c.1183G > T;
p.E395X mutation and a duplication of exon 9; because
the co-occurrence of 3 mutations in the same gene is
unlikely we designed an additional forward primer that
flanked the E395X mutation as close as possible on the 5'
side; sequencing of the PCR product generated by ampli-
fication with this new primer and primer PRKNexon11R
showed the E395X in a heterozygote state, suggesting that
the duplication of exon 9 (and presumably exon 10,
which we were unable to assay) interfered with the origi-
nal PCR and sequencing reaction. Thus in Table 2 this
mutation is denoted as a compound heterozygous E395X/
exon 9 duplication mutation.
Two samples tested positive for the LRRK2 c.6055G > A;
p.G2019S mutation, sample S12 and sample S7. Notably,
analysis of sample S7 also showed a heterozygous dupli-
cation of PRKN exon 9. Screening of variants E395X,
G2019S and 154delA in 252 control chromosomes failed
to reveal any control subjects harboring these mutations.
Additionally, we have identified three patients with heter-
ozygous mutations in PRKN: one harboring the T240M
variant; another with a deletion of exons 8 through 11 and
one with an exon 8 duplication. Furthermore, we have
found one patient with two heterozygous dosage variants:
an exon 2 deletion and an exon 5 duplication.
No mutations were found in SNCA or PINK1.
Discussion
We present in this study a detailed mutation analysis of
PRKN, PINK1, SNCA and LRRK2. We have included PD
patients with a positive family history (n = 19 age at onset
<50 years, n = 20 age at onset ≥ 50 years), or early-onset
sporadic disease (n = 27) in order to maximize our
chances of identifying mutations. This approach has led
us to find 6 subjects (9.1%) with pathogenic mutations in
LRRK2 or PRKN, in addition to 4 variants of unknown sig-
nificance in 4 patients.
In our previous report [15] we showed that the c.6055G >
A; p.G2019S LRRK2 mutation underlies about 6% of late-
onset PD in the Portuguese population. While we did not
find any c.6055G > A; p.G2019S carriers in the 20 late-
onset patients studied here, we did identify c.6055G > A;
p.G2019S in 2 of 46 early-onset cases. One of these indi-
viduals also carried a heterozygous duplication of PRKN
exon 9 consistent with the notion of digenic parkinson-
ism, as previously described [22]. This patient presented
no family history consistent with PD, while the other
LRRK2 patient had positive family history. Taking into
account the removal of samples previously found to carry
the c.6055G > A; p.G2019S mutation we calculate that
this mutation is present in 9 probands out of the entire
series of 132 patients; this represents 2 of 46 early-onset
patients, counting only sporadic cases and a single
proband from each family (4.3%) and 7 of 76 late-onset
Table 2: Variants found
Sample Gene Nucleotide change Amino acid change Copy variation Exon Zygosity AAO
S1 PRKN 154delA N52fsX80 N/A 2 Homo 30
S2 PRKN 154delA N52fsX80 N/A 2 Homo 35
S3 PRKN 154delA N52fsX80 N/A 2 Homo 21
S4 PRKN G1183T E395X* N/A 11 Het 53
PRKN N/A N/A Duplication 9 Het
S5 PRKN C719T# T240M N/A 6 Het 55
S6 PRKN N/A# N/A Duplication 8 Het 33
S7 PRKN N/A N/A Duplication 9 Het 38
LRRK2 G6055A G2019S N/A 41 Het
S8 PRKN N/A# N/A Deletion 8 – 11 Het 32
S10 PRKN N/A# N/A Deletion 2 Het 35
PRKN N/A# N/A Duplication 5 Het
S12 LRRK2 G6055A G2019S N/A 41 Het 41
Homo: Homozygosity; Het: heterozygosity; * previously undescribed mutation; # Variants of unknown significance e.g pathogenicity not confirmed 
herein. AAO: Age at onset.Page 3 of 6
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proband from each family (9.2%).
We found several PRKN mutations as either homozygous
or compound heterozygous loss of function changes. The
N52fsX80 variant was the most frequent mutation identi-
fied in PRKN. It was present as a homozygous mutation in
three unrelated young onset patients (of 46, 6.5%). Anal-
ysis of relatives of these patients failed to show any heter-
ozygous carriers of this mutation with parkinsonism. We
identified a heterozygous deletion of exon 2 and a dupli-
cation of exon 5 in PRKN in one early-onset patient with
Electropherograms of the pathogenic point mutations foundFigu e 1
Electropherograms of the pathogenic point mutations found. image of the four pathogenic variants discovered in our 
series. A) chromatogram of the homozygous 154delA in PRKN exon 2, predicted to cause the N52fsX80 aminoacid change; B) 
chromatogram of the new mutation G1183T in PRKN exon 11, apparently homozygous, predicted to cause a premature stop 
codon at position 395; C) chromatogram of the heterozygous G6055A in LRRK2 exon 41, predicted to cause the G2019S 
change; D) chromatogram of the heterozygous C719T variant in PRKN exon 6, predicted to cause the T240M change.Page 4 of 6
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that was available for testing was the sibling of S10 who
presented with the same two variants, albeit with a
remarkably different age at onset (50 years vs 35 years of
patient S10) (Figure 2). While parsimony suggests that
these mutations are in trans we were unable to unequivo-
cally establish phase as DNA was unavailable from other
family members. We also identified a heterozygous dele-
tion of exons 8 through 11 in a female patient with an age
at onset of 32 years. Additional family members were una-
vailable, so we were unable to determine whether this
mutation represented a single contiguous mutation or
two mutations existing in trans and thus the pathogenicity
of the observed changes remains unknown. We identified
a novel mutation in PRKN exon 11 (E395X) as a hetero-
zygous alteration. This patient also possessed a hetero-
zygous duplication of exon 9. The pathogeneicity of the
new E395X mutation is clear since it is a nonsense muta-
tion that occurs upstream of a functional domain of the
protein. Of these patients presenting either homozygous
or clear compound heterozygous mutations in PRKN,
four (80%) have an age at onset below 40 years. Only one
(patient S4) presents late-onset disease (53 years).
In addition we identified several PRKN variants of
unknown significance. The T240M alteration, an exon 8
deletion and an exon 8 duplication were each identified as
heterozygous mutations in single patients. In the absence
of additional mutations in PRKN in these subjects, we
have not considered these as disease causing variants in
these patients. We make this statement with caution, since
we cannot rule out copy number mutations in exons 3 or
10, which we were unable to assay effectively.
Conclusion
It is now clear that genetics plays an important role in the
pathogenesis of PD. Specifically, in the Portuguese popu-
lation, we have found a reasonable number of mutations:
the frequency of the c.6055G > A; p.G2019S is one of the
highest in Europe, and in the present paper we have found
that 8.7% (4 out of 46 cases) of early-onset cases are
attributable to PRKN mutations. Similar to other reports
we found PINK1 and SNCA mutations to be a rare cause
of disease in our families [23]. Taken as a whole these
results have implications mainly for clinicians in Portugal;
in particular showing that genetic screening may aid the
diagnosis of PD in this population. However, even with
the combination of gene dosage and sequencing, a signif-
icant proportion of mutations might remain undetected,
probably due to the size and the complexity of the PRKN
gene. In this way, negative results should be interpreted
with caution, as well as heterozygous mutations in this
gene.
Dosage plotsFigur 2
Dosage plots. Dosage plot of the variants found in PRKN in sample S10 and its sibling here denoted as S9. Represented are 
exons 1, 2, 4–9, 11 and 12. Each exon was compared with the beta-globin gene and normalized to a control DNA.Page 5 of 6
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